The Researcher’s Guide to Using Antigen-Specific T Cells for Immunologic Discovery
It’s an area in which we’ve invested a lot of time and resources so researchers like you can have the right tools to learn more about our incredible immune systems and discover tomorrow’s cures and treatments.
Explore some of our best resources for advancing your working knowledge of antigen-specific T cells.
Table of Contents
- How Can Studying Antigen-Specific T cells Help Us Make CAR-T Cells More Powerful? (Blog Post)
- What Are Your Antigen-Specific T Cell Capabilities? (Blog Post)
- How Can I Use Antigen-Specific T Cells? (Blog Post)
- Surface Antigen Expression (Blog Post)
- New Proinsulin-Specific T Cells for Diabetes Research (Blog Post)
- NY-ESO-1-Specific T Cell Lines for Cancer Immunotherapy (Blog Post)
- Antigen-Specific T Cell Assay (Protocol)
- Anti-Leukemia T Cells (Blog Post)
- Using Anti-MART-1 T Cells for Melanoma Immunotherapy (Blog Post)
- T Cell Antigen Recognition (Blog Post)
- Using the Epstein-Barr Virus to Study the Immune System (Blog Post)
- New T Cell Line Specific for Herpes Virus (Blog Post)
- Publications Featuring Cellero Cells (Research Articles)
- Anti-HPV-E7 T Cells to Aid in HPV Research (Blog Post)
- Shop Our Current Inventory of Antigen-Specific T Cells (Products)
How Can Studying Antigen-Specific T cells Help Us Make CAR T Cells More Powerful? (Blog Post)
In the last few years, CAR T cell-based immunotherapies have shown great promise in clinical trials, and scientists are continuing to advance their knowledge with hopes of developing CAR T cell therapies for a range of cancers.
CAR T cells are designed to essentially function as antigen-specific T cells, which can be difficult to collect and grow outside of the body. But antigen-specific T cells can still play a vital role in helping us better understand CAR T cells and make them more powerful in fighting cancer.
Learn more about the role of antigen-specific T cells in cancer research.
What Are Your Antigen-Specific T Cell Capabilities? (Blog Post)
The success with chimeric antigen receptor T cells (CAR-T cells) has reinvigorated interest in T cells and their natural recognition of target antigens.
With so much demand for antigen-specific T cells from pharmaceutical companies to academic research labs, we have developed several antigen-specific T cell lines over the years, most of which are exclusive products you’ll only find at Cellero.
How Can I Use Antigen-Specific T Cells? (Blog Post)
Antigen-specific T cells have many excellent use cases in the lab for early-stage research and discovery.
As we continue to develop novel antigen-specific T cell lines — including those specific to tumors, diabetes, and viruses — more use cases are coming to light.
If you’re working in an academic or biopharma research lab, consider antigen-specific T cells to help you achieve some of the following results.
Surface Antigen Expression (Blog Post)
Surface antigens, or cell markers, are a handy way for scientists to classify cells based on cell type and function, which is beneficial for early-stage research as well as disease diagnosis and treatment.
Learn more about surface antigen expression and using cell markers as activation measures.
New Proinsulin-Specific T Cells for Diabetes Research (Blog Post)
Type 1 diabetes, characterized by the loss of beta cells in the pancreas, affects approximately 1.25 million Americans. That number is expected to rise dramatically to 5 million by 2050.
When these beta cells die, production of insulin declines and blood glucose levels increase uncontrollably. The death of these beta cells is widely believed to be the result of an autoimmune process and researchers have discovered T cells and antibodies directed against beta cell antigens in people with type 1 diabetes.
Expand your research horizons with our newest antigen-specific T cell line that recognizes a proinsulin peptide.
NY-ESO-1-Specific T Cell Lines for Cancer Immunotherapy (Blog Post)
The NY-ESO-1 (New York Esophageal Squamous Cell Carcinoma 1) antigen is restricted to germ and placental cells, with re-expression in tumor cells. NY-ESO-1 expression has been associated with many cancer types.
As researchers continue to search for tumor-specific antigens for the development of immune-based modalities, NY-ESO-1 is considered to be an excellent candidate for immunotherapies. Its limited expression in normal cells, wide-ranging expression in tumors, and limited off-target toxicities make it a promising antigen.
Learn more about our anti-NY-ESO-1 T cells.
Anti-Leukemia T Cells (Blog Post)
This T cell line recognizes the WT1 tumor antigen, which gets its name from a gene that was originally discovered in Wilms’ tumor, a type of kidney malignancy affecting 1 in 10,000 infants.
Since its discovery, scientists have found the WT1 antigen to be overexpressed in many tumors, including acute myelocytic, acute lymphocytic, and chronic myelocytic leukemia, and several solid tumors, including lung cancer and breast cancer. This widespread overexpression makes WT1 an attractive target for immunotherapy research and for developing WT1-based T cell therapies.
Using Anti-MART-1 T Cells for Melanoma Immunotherapy (Blog Post)
MART-1 (melanoma antigen recognized by T cells 1) is a “widely shared melanoma antigen recognized by the T lymphocytes of patients with established malignancy.”
MART-1 is one of the oldest identified tumor antigens and is a protein found on normal melanocytes in the skin and retina. It is also found in most melanomas, cancers that originate in melanocytes.
To aid in the advancement of MART-1 immunotherapy research, we have developed a T cell line specific to the MART-1 antigen.
Using the Epstein-Barr Virus to Study the Immune System (Blog Post)
The Epstein-Barr virus (EBV) is one of the most prevalent infections, found in about 95% of the adult population. EBV is a lifelong infection with ties to many diseases.
Although infected individuals often build adaptive immunity to EBV and are asymptomatic, EBV is associated with infectious mononucleosis, several types of cancer such as Hodgkin’s lymphoma, and autoimmune diseases including multiple sclerosis and HIV.
We offer an EBV specific T cell line that produces IFNg when stimulated with an EBV-derived peptide bound to HLA-A*0201.
New T Cell Line Specific for Herpes Virus (Blog Post)
HSV causes cold sores, ocular disease and genital lesions. About 48% Americans ages 14 to 49 carry HSV-1 and 12% of the same population carry HSV-2, but many show no symptoms or suffer nothing more than the occasional cold sore.
Due to the widespread occurrence of the complex and currently incurable virus, combined with the potentially lethal consequences of transmission, it’s an important virus to study for vaccine development and treatment.
Anti-HPV-E7 T Cells to Aid in HPV Research (Blog Post)
Scientists have made many contributions to the study of the proteins produced by the human papillomavirus, including the E7 protein, which has been linked to the transformation of normal cells to cancerous cells. We developed a new addition to our exclusive collection of antigen-specific T cells to help researchers study HPV and develop future vaccinations and treatments.
Our Anti-HPV E7 T Cells have the potential to detect and kill tumor cells that carry the E7 protein and express the HLA-A*0201 antigen, both common in Americans infected with HPV.